Another Humira biosimilar gets FDA nod, as Korea's Samsung Bioepis joins launch wait list July 29, 2019 By Jihyun Kim HONG KONG – Samsung Bioepis Co. Ltd., a South Korean biosimilar developer, said the FDA approved its July 2018 application for Hadlima (adalimumab-bwwd), a biosimilar referencing Abbvie Inc. blockbuster TNF-blocker Humira (adalimumab).Read More
